ArticleBrain communications2025
Unravelling differences and hallmarks in suspected diffuse low-grade gliomas: a multicentre database study.
Article in Brain communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The natural history of suspected diffuse low-grade gliomas (DLGG) depends heavily upon the molecular status. To fully comprehend this integrated information preoperatively, a clinical phenotype incorporating both clinical and radiological information may be of value. We aimed to analyse this systematically in a large multicentre study to identify clinical/radiological phenotypes of DLGG molecular subgroups at the onset. Patients from nine Scandinavian centres, with confirmed World Health Organization (WHO) grade 2 at the time of diagnosis (according to the WHO 2016/2007 classification), known molecular status [isocitrate dehydrogenase (IDH) status and 1p19q codeletion status] and preoperative images of adequate quality, were analysed. MRI-based tumour volume segmentation was used to create a frequency map of their locations in the Montreal Neurological Institute space. A Brain-Grid (BG) system was also used for tumour invasiveness analysis. Variables were analysed for each subgroup of DLGG with regression analyses. A total of 235 patients were included in the study. The three molecular subgroups differed in age, tumour location, epileptic onset and cognitive status. Seizure onset was linked to the number of BG voxels and the A3C2S2 location in all three molecular subgroups. Cognitive deficits were related to increasing age (IDH-mutated oligodendrogliomas), female gender (IDH-wildtype) and tumour volume (oligodendrogliomas). Patients with IDH-mutated astrocytomas (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.